Fundraising Fox
CytoDyn
OTC: CYDYVancouver, US · Delaware corporation · 1 known investors
Find your way into CytoDyn
Sign up to see every warm intro you have to CytoDyn
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CytoDyn team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CytoDyn is a biopharmaceutical company conducting clinical trials, including a Phase 2 colorectal cancer trial.
Founders & leadership
JP
Jacob P. LalezariExecutive
NZ
Nadar Z. PourhassanExecutive
AT
Andrew T. Libby, Jr.Executive
KJ
Kenneth J. Van NessExecutive
Board
JG
Jordan G. NaydenovBoard director
CC
Carl C. DockeryBoard director
TD
Tanya D. UrbachBoard director
SM
Stephen M. SimesBoard director
Investors · 1
Yorkville AdvisorsreportedMountainside
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$150.4M disclosed across 16 of 18 rounds · 1900–2026
▶$18.6MraisedMay 2026 · 194 investors · PharmaceuticalsRule 506(b)
▶$18.6MraisedMay 2026 · 194 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Tanya D. UrbachDirector
- Stephen M. SimesDirector
- Lishomwa C. Ndhlovu, M.D., Ph.D.Director
- Robert E. HoffmanExecutive Officer
- Jacob P. LalezariExecutive Officer
- Karen J. Brunke, Ph.D.Director
- Tyler BlokExecutive Officer
- Ryan M. DunlapDirector
- Offering amount
- $18.6M
- Amount sold
- $18.6M
- Minimum investment
- $15K
- Sales commissions
- $2.3M
- Proceeds to insiders
- $1.6M
- Placement agents
- Paulson Investment Company
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21.8MraisedSep 2022 · 166 investors · PharmaceuticalsRule 506(c)
▶$21.8MraisedSep 2022 · 166 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Ryan DunlapDirector
- Scott A. KellyExecutive Officer, Director
- Arvin Cyrus ArmanExecutive Officer
- Karen J. BrunkeDirector
- Antonio MigliareseExecutive Officer
- Lishomwa C. NdhlovuDirector
- Tanya Durkee UrbachDirector
- Nitya G. RayExecutive Officer
- Offering amount
- $21.8M
- Amount sold
- $21.8M
- Minimum investment
- $5K
- Sales commissions
- $2.8M
- Proceeds to insiders
- $600K
- Placement agents
- Paulson Investment Company
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$11.4MraisedDec 2021 · 118 investors · BiotechnologyRule 506(b)
▶$11.4MraisedDec 2021 · 118 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Antonio MigliareseExecutive Officer
- Christopher RecknorExecutive Officer
- Tanya Durkee UrbachDirector
- Harish SeethamrajuDirector
- Jordan G. NaydenovDirector
- Nitya G. RayExecutive Officer
- Nader Z. PourhassanExecutive Officer, Director
- Lishomwa C. NdhlovuDirector
- Scott A. KellyExecutive Officer, Director
- Offering amount
- $53.6M
- Amount sold
- $11.4M
- Minimum investment
- $10K
- Sales commissions
- $6.5M
- Placement agents
- Paulson Investment Company
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedSep 2021 · 6 investors · BiotechnologyRule 506(b)
▶$2.9MraisedSep 2021 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott A Kelly, M.D.Executive Officer, Director
- Gordon A. GardinerDirector
- Nitya G. Ray, Ph.D.Executive Officer
- Nader Z. Pourhassan, Ph.D.Executive Officer, Director
- Samir R. Patel, M.D.Director
- Christopher Recknor, M.D.Executive Officer
- Antonio Migliarese, C.P.A.Executive Officer
- Alan P. TimminsDirector
- Jordan G. NaydenovDirector
- Offering amount
- $25.2M
- Amount sold
- $2.9M
- Minimum investment
- $250K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MofferedDec 2020 · BiotechnologyRule 506(b)
▶$1.2MofferedDec 2020 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael D. MulhollandExecutive Officer
- Nitya G. Ray, Ph.D.Executive Officer
- Mahboob Rahman, M.D., Ph.D.Executive Officer
- Arian ColachisExecutive Officer
- Scott Kelly, M.D.Executive Officer, Director
- Alan P. TimminsDirector
- Jordan G. NaydenovDirector
- Nader Z Pourhassan, Ph.DExecutive Officer, Director
- Samir R. Patel, M.D.Director
- Offering amount
- $1.2M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedDec 2020 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedDec 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott Kelly, M.D.Executive Officer, Director
- Nader Z Pourhassan, Ph.DExecutive Officer, Director
- Jordan G. NaydenovDirector
- Alan P. TimminsDirector
- Samir R. Patel, M.D.Director
- Michael D. MulhollandExecutive Officer
- Nitya G. Ray, Ph.D.Executive Officer
- Mahboob Rahman, M.D., Ph.D.Executive Officer
- Arian ColachisExecutive Officer
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $1M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.6MraisedApr 2020 · 3 investors · BiotechnologyRule 506(b)
▶$7.6MraisedApr 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nader Z PourhassanExecutive Officer, Director
- David F WelchDirector
- Craig EastwoodExecutive Officer
- Alan P TimminsDirector
- Jordan G NaydenovDirector
- Arian ColachisExecutive Officer
- Scott A KellyDirector
- Offering amount
- $11.4M
- Amount sold
- $7.6M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$882KraisedMar 2020 · 1 investors · BiotechnologyRule 506(b)
▶$882KraisedMar 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nader Z PourhassanExecutive Officer, Director
- Craig EastwoodExecutive Officer
- Jordan G NaydenovDirector
- Arian ColachisExecutive Officer
- Scott A KellyDirector
- David F WelchDirector
- Alan P TimminsDirector
- Offering amount
- $1.2M
- Amount sold
- $882K
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
TipRanksFinancial analysis and stock research platform.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Companies working in the same space as CytoDyn.
Frequently asked questions
- What does CytoDyn do?
- CytoDyn is a biopharmaceutical company conducting clinical trials, including a Phase 2 colorectal cancer trial.
- Who are CytoDyn's investors?
- CytoDyn's investors include Yorkville Advisors.
- How much funding has CytoDyn raised?
- CytoDyn has disclosed $150.4M raised across 16 of its 18 known rounds.
- Where is CytoDyn headquartered?
- CytoDyn is headquartered in Vancouver, US.